atreleuton

Small moleculeexperimental

Clinical trial activity

3 trials · 7 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
3
Phase 3
0
Phase 4
0

Earliest trial started Jul 1, 2006 (NCT00358826)

Timeline

2000s

  1. Jan 1, 2006

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

C[C@H](C#Cc1ccc(Cc2ccc(F)cc2)s1)N(O)C(N)=O
Mol. weight
318.37 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • a-85761
  • a-85761
  • a-85761.0
  • a-85761.0
  • abbott-85761
  • abbott-85761
  • abt 761
  • abt-761
  • abt-761
  • abt-761
  • atreleuton
  • atreleuton
  • atreleuton
  • atreleuton
  • n-(3-(5-((4-fluorophenyl)methyl)-2-thienyl)-1-methyl-2-propynyl)-n-hydroxyurea
  • via2291
  • via 2291
  • via-2291
  • via-2291
  • via-2291

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT00552188Phase 2Oct 1, 2007Harvard University, Icahn School of Medicine at Mount Sinai, Tallikut Pharmaceuticals, Inc., University of Massachusetts, University of Montreal, VIA Pharmaceuticals, Winthrop University
NCT00352417Phase 2Jul 1, 2006Tallikut Pharmaceuticals, Inc., VIA Pharmaceuticals
NCT00358826Phase 2Jul 1, 2006Tallikut Pharmaceuticals, Inc., University of Montreal, VIA Pharmaceuticals
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (7)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Tallikut Pharmaceuticals, Inc.For profit3312006
VIA PharmaceuticalsFor profit3012006
University of MontrealAcademic/Hospital2012006
Harvard UniversityAcademic/Hospital1012007
Icahn School of Medicine at Mount SinaiAcademic/Hospital1012007
University of MassachusettsAcademic/Hospital1012007
Winthrop UniversityAcademic/Hospital1012007
7 organizations
Page 1 / 1